Relmada Therapeutics reports preclinical data on its novel psilocybin

Relmada Therapeutics announced that new preclinical data on its novel psilocybin will be highlighted in a poster presentation at the American Association for the Study of Liver Diseases, or AASLD, The Liver Meeting 2023, being held November 10-14, 2023, in Boston, MA. The data demonstrate the beneficial effect of non-psychedelic/low dose psilocybin on multiple metabolic parameters in a rodent model of metabolic dysfunction-associated steatotic liver disease, or MASLD. Mice were fed a high fructose, high fat diet, or HFHFD, for 17 weeks to induce MASLD, along with hyperglycemia, hyperlipidemia and significant weight gain. One group of MASLD mice was treated with low-dose psilocybin daily and a second with vehicle daily by oral gavage while continuing on HFHFD. Standard diet-fed mice were used as controls. Body-weight and food intake were assessed weekly. Key statistically significant results in psilocybin-treated mice relative to HFHFD vehicle-treated mice include: Significantly reduced hepatic steatosis; 12% reduction in body weight gain with no reduction in food intake; Significant decrease in fasting blood glucose level and AUC in an Oral Glucose Tolerance Test